Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
Paola Guglielmelli, Barbara Mora, Francesca Gesullo, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1550-1559
Closed Access | Times Cited: 11

Showing 11 citing articles:

Thrombosis‐Driven Disease Progression in JAK2‐Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk‐Based Management
Tiziano Barbui, Valerio De Stefano, Elena Rossi, et al.
American Journal of Hematology (2025)
Closed Access
Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study
Seug Yun Yoon, Sung‐Soo Yoon, Deok‐Hwan Yang, et al.
International Journal of Cancer (2025)
Open Access
Impact of ELN clinical signs and symptoms on the thrombotic risk in Polycythemia Vera patients treated with front-line hydroxyurea
Francesca Palandri, Massimo Breccia, Elena Maria Elli, et al.
Research Square (Research Square) (2025)
Closed Access
Treatment‐associated decline inJAK2V617F allele burden in polycythemia vera: What does it mean?
Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1459-1461
Closed Access | Times Cited: 2
The evolving landscape of polycythemia vera therapies
Juana Martínez, Shivani Handa, Alexander Skorodinsky, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 11, pp. 1439-1452
Closed Access
Disappearance of a chromosomal abnormality in a young patient with polycythemia vera treated with ropeginterferon alfa-2b
Rina Hosoda, Yoshinori Hashimoto, Kentaro Hara, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3825-3827
Closed Access
Prognostic and Predictive Models in Myelofibrosis
Barbara Mora, Cristina Bucelli, Daniele Cattaneo, et al.
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 5, pp. 223-235
Open Access
Ruxolitinib for myelofibrosis: The earlier, the better?
Prithviraj Bose, Pankit Vachhani
Cancer (2024) Vol. 130, Iss. 24, pp. 4224-4226
Open Access
Reduction of clonal hematopoiesis mutation burden in coronary patients treated with low-dose colchicine
Jean‐Claude Tardif, Lambert Busque, Steve Geoffroy, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety
Lucia Masarová, John Mascarenhas, Raajit K. Rampal, et al.
Cancer (2024)
Closed Access
Novel approaches in myelofibrosis
Steffen Koschmieder
HemaSphere (2024) Vol. 8, Iss. 12
Open Access
Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms
Judith M. Bliss, Spencer Krichevsky, Joseph M. Scandura, et al.
Frontiers in Hematology (2024) Vol. 3
Open Access
Page 1

Scroll to top